Repligen (NASDAQ:RGEN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The brokerage currently has a $96.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 12.94% from the stock’s previous close.
According to Zacks, “Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. “
RGEN has been the subject of several other research reports. BidaskClub downgraded Waterstone Financial from a “hold” rating to a “sell” rating in a report on Friday, June 21st. ValuEngine raised United Overseas Bank from a “sell” rating to a “hold” rating in a report on Monday, June 17th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Repligen has an average rating of “Buy” and a consensus target price of $70.50.
RGEN opened at $85.00 on Friday. The company has a 50-day moving average of $78.38. Repligen has a 1 year low of $45.00 and a 1 year high of $87.42. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.18 and a quick ratio of 1.84. The stock has a market capitalization of $4.01 billion, a price-to-earnings ratio of 116.44, a PEG ratio of 5.17 and a beta of 1.10.
Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.02. Repligen had a return on equity of 6.35% and a net margin of 10.11%. The company had revenue of $60.63 million for the quarter, compared to analyst estimates of $55.09 million. During the same quarter in the previous year, the firm earned $0.17 earnings per share. The firm’s quarterly revenue was up 35.3% compared to the same quarter last year. As a group, research analysts predict that Repligen will post 0.94 earnings per share for the current fiscal year.
In other Repligen news, Director Karen A. Dawes sold 1,295 shares of the firm’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $77.35, for a total value of $100,168.25. Following the completion of the sale, the director now owns 118,329 shares of the company’s stock, valued at $9,152,748.15. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Glenn L. Md Cooper sold 5,000 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $66.94, for a total value of $334,700.00. Following the completion of the sale, the director now directly owns 35,975 shares of the company’s stock, valued at approximately $2,408,166.50. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Huntington National Bank acquired a new stake in Repligen in the first quarter worth about $25,000. Royce & Associates LP boosted its holdings in Repligen by 40.6% in the first quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 145 shares in the last quarter. Mascoma Wealth Management LLC acquired a new stake in shares of Repligen during the first quarter worth about $41,000. Private Capital Group LLC lifted its holdings in shares of Repligen by 675.3% during the first quarter. Private Capital Group LLC now owns 721 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 628 shares during the period. Finally, South Dakota Investment Council acquired a new stake in shares of Repligen during the first quarter worth about $83,000. 84.90% of the stock is owned by institutional investors and hedge funds.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Article: Why is cost of goods sold important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.